ClinConnect ClinConnect Logo
Search / Trial NCT03229460

High Flow Nasal Oxygen Therapy in Perioperative Period of the Adult With Hypercapnic and Hypoxemic Respiratory Faliure

Launched by XINHUA HOSPITAL, SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE · Jul 23, 2017

Trial Information

Current as of August 02, 2025

Unknown status

Keywords

ClinConnect Summary

Humidified high flow nasal oxygen therapy decreases dilution of the inhaled oxygen and, by matching patient's peak flow, allows accurate delivery of the set FiO2 throughout the whole inspiratory phase.The purpose of this study is to determine the impact of hign-flow nasal therapy on adult hypercapnic respiratory failure by comparing with nasal continuous positive airway pressure

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Hypoxemic and no hypercapnic acute respiratory failure :
  • severe dyspnea at rest with a respiratory rate \>25 breaths/min
  • PaO2/FiO2 \<300
  • PaCO2 \<45 mmHg,
  • Exclusion Criteria:
  • age \<18 years
  • NPPV contraindications
  • past history of respiratory chronic disease (COPD, cystic fibrosis...)
  • cardiac pulmonary edema
  • Pre-defined intubation
  • other than respiratory organ failure : systolic pressure \<90 mmHg,current treatment with epinephrine or norepinephrine, decreased level of consciousness ( Glasgow score ≤ 12)
  • profound aplasia (white cells count \<1000/mm 3)

About Xinhua Hospital, Shanghai Jiao Tong University School Of Medicine

Xinhua Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, is a prominent clinical research institution renowned for its commitment to advancing medical science and patient care. Located in Shanghai, China, the hospital integrates clinical practice, education, and research, fostering innovation in various medical fields. With state-of-the-art facilities and a multidisciplinary team of experts, Xinhua Hospital conducts rigorous clinical trials aimed at evaluating new therapies and improving treatment outcomes. Its dedication to ethical standards and patient safety positions it as a leader in the global clinical research landscape.

Locations

Shanghai, Shanghai, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials